Profound Medical Corp. (PROF)
NASDAQ: PROFHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PROF stock chart
Technical analysisKey statistics
All statistics- Market cap
- $233.68M
- EPS (TTM)
- -$0.94
- Dividend yield
- None
- 52-week range
- 4.80 – 8.95
- Day range
- 6.26 – 6.65
- Volume / Avg
- 144.19K / 208.29K
- Beta
- —
- Shares outstanding
- 36.63M
52-week range
PROF stock today
Profound Medical (PROF) closed at $6.38 on Nov 20, down 3.19% (-$0.21), versus the S&P 500's 3.70% decline. Shares are 28.7% below their 52-week high of $8.95, set on Jan 13, 2026 and 32.9% above the 52-week low of $4.80, in the middle of the past year's range. PROF is down 18.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 6.2%.
Profound Medical has posted a net loss over the last twelve months (EPS of -$0.94), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Profound Medical
Company profileProfound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Dr. Arun Swarup Menawat MBA, Ph.D.
- Headquarters
- Mississauga, ON
- Employees
- 162
- Website
- profoundmedical.com
Financial highlights
Full financialsIn fiscal 2025, Profound Medical generated $16.1 million in revenue, up 50.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Profound Medical reported a net loss of $42.6 million, compared with a loss of $27.8 million a year earlier. Gross margin was 70.8% (up from 65.9%) and operating margin -256.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $16.10M | $10.68M | $7.20M | $6.68M | $6.87M |
| Growth | +50.73% | +48.35% | +7.75% | -2.79% | -5.90% |
| Net income | $-42.57M | $-27.82M | $-28.32M | $-28.67M | $-30.70M |
| EPS (diluted) | $1.41 | $1.12 | $1.34 | $1.38 | $1.50 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$11.14+74.61%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.21 vs $-0.19
- Surprise
- -10.53%
PROF news
All PROF news- Profound Medical to Participate in the Stifel 2026 Healthcare ConferenceGlobeNewswirePRN, PROF
- Profound Medical (PROF) Q3 2026 Earnings Call TranscriptNasdaq
- Profound Medical Corp. Announces Fall In Q3 IncomeNasdaq
- Healthcare Stocks Trade Higher: CDNA Gains 20%, REGN Adds 12%, PROF Climbs 10%, AZN Advances 7%NasdaqAZN, CDNA, PROF, REGN
- Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue GrowthGlobeNewswirePRN, PROF
- Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ WebinarGlobeNewswirePRN, PROF
- TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion OpportunityGlobeNewswirePRN, PROF
- Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate CareNasdaqPROF, TLX
Profound Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OSUROraSure Technologies Inc. | 3.46 | -4.16% | $238.90M | vs PROF |
| CLPTClearPoint Neuro Inc. | 6.91 | -5.47% | $221.49M | vs PROF |
| OFIXOrthofix Medical Inc. | 6.07 | -4.26% | $247.41M | vs PROF |
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs PROF |
| KTWOK2 Capital Acquisition Corporation Class A | 10.13 | 0.00% | $203.02M | vs PROF |
| PDEXPro-Dex Inc. | 63.00 | -0.77% | $201.60M | vs PROF |
| UTMDUtah Medical Products Inc. | 69.49 | -2.07% | $198.01M | vs PROF |
| NPCENeuropace Inc. | 7.95 | -2.33% | $273.89M | vs PROF |
Indexes, lists and sector
Profound Medical stock FAQ
What is Profound Medical's stock price today?
PROF last traded at $6.38 as of Nov 20, 4:00 PM EST, down 3.19% on the day. Prices are delayed at least 15 minutes.
Who is Profound Medical's CEO?
Dr. Arun Swarup Menawat MBA, Ph.D. is the chief executive officer of Profound Medical Corp., which has about 162 employees.
What is the PROF 52-week high?
The 52-week high for PROF is $8.95 and the 52-week low is $4.80. The stock is currently 28.7% below its high.